The TAP Study is a research project to see if a medicine called BE1116 can help people with serious injuries and heavy bleeding to survive better. In this study, volunteers will receive either BE1116 or a placebo (a substance with no active medicine) through an IV (a tube that delivers medicine directly into the vein). This study is "double-blind," which means neither the participants nor the doctors know who gets BE1116 and who gets the placebo. This helps ensure the study results are fair and accurate.

Eligibility: To join, participants need to be at least 15 years old (in some places, the age is higher) and weigh at least 50 kilograms (about 110 pounds). They should have a serious injury with major bleeding or need a lot of blood transfusions.

• This study involves a single visit for the IV infusion.
• Participants will be randomly selected to receive either BE1116 or a placebo.
• There are risks involved, such as possible side effects from the IV infusion.

It is important to know that some people, like those with certain head injuries or on specific blood-thinning medicines, cannot join this study. If you think you might qualify, consider the risks and benefits before deciding to participate.